

S4 Table. Number of patients at each landmarks according to overall, and different types and numbers of organs involved

Landmarks (patients, N)	No. (n=425)	Progression-free survival				Overall survival			
		2-Month (n=328)	3-Month (n=265)	6-Month (n=191)	9-Month (n=146)	2-Month (n=419)	3-Month (n=416)	6-Month (n=358)	9-Month (n=308)
Overall irAEs	127 (29.9)	58 (17.7)	68 (25.7)	71 (37.2)	63 (43.2)	66 (15.8)	79 (19.0)	95 (26.5)	90 (29.2)
The type of organ involved									
Skin	42 (9.9)	26 (7.9)	30 (11.3)	25 (13.1)	21 (14.4)	28 (6.7)	32 (7.7)	35 (9.8)	34 (11.0)
Thyroid	39 (9.2)	16 (4.9)	22 (8.3)	26 (13.6)	23 (15.8)	16 (3.8)	25 (6.0)	34 (9.5)	31 (10.1)
Pneumonitis	27 (6.4)	5 (1.5)	8 (3.0)	9 (4.7)	8 (5.5)	6 (1.4)	9 (2.2)	12 (3.4)	13 (4.2)
Hepatic	25 (5.9)	2 (0.6)	11 (4.2)	15 (7.9)	13 (8.9)	3 (0.7)	11 (2.6)	18 (5.0)	18 (5.8)
No. of organs involved									
0	298 (70.1)	270 (82.3)	197 (74.3)	120 (62.8)	83 (56.8)	353 (84.2)	337 (81.0)	263 (73.5)	218 (70.8)
1	89 (20.9)	47 (14.3)	52 (19.6)	52 (27.2)	47 (32.2)	55 (13.1)	62 (14.9)	69 (19.2)	63 (20.4)
≥2	38 (9.0)	11 (3.4)	16 (6.1)	19 (10.0)	16 (11.0)	11 (2.7)	17 (4.1)	26 (7.3)	27 (8.8)

Values are presented as number (%). irAEs, immune-related adverse events.